Paraganglioma Market Report 2026

Paraganglioma Market Overview

• Paraganglioma market size has reached to $3.02 billion in 2025 • Expected to grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 4.4% • Growth Driver: Rising Investments In Oncology Research And Medicine A Catalyst For Growth In The Market • Market Trend: Advancement In Oral HIF-2α Inhibitors For Paraganglioma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Paraganglioma Market?

Paraganglioma is a rare neuroendocrine tumor originating from paraganglia, clusters of cells linked to the autonomic nervous system. Typically found in the head, neck, chest, or abdomen, these tumors may produce excess hormones and pose a risk of malignancy. Early diagnosis is essential for effective management and preventing complications. The main types of paraganglioma are sympathetic paragangliomas, parasympathetic paragangliomas, carotid paragangliomas, cervical paragangliomas, jugular paragangliomas, secretory paragangliomas, and temporal paragangliomas. Sympathetic paragangliomas are rare neuroendocrine tumors that develop in the sympathetic nervous system and often produce catecholamines. It originates from various origins, such as the head and neck, abdomen, pelvis, and others. The various treatment types include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and others. It is distributed through various distribution channels such as hospital pharmacies, drug stores, retail pharmacies, and online pharmacies and is used by several end-users, including hospitals, specialty clinics, cancer research institutes, and others.

What Is The Paraganglioma Market Growth Forecast?

The paraganglioma market size is expected to see steady growth in the next few years. It will grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to advancements in biologic and immunotherapy drugs, increasing prevalence of autoimmune and infectious eye disorders, growth of teleophthalmology and digital monitoring, rising investments in ai-based diagnostics, expansion of hospital and specialty clinic distribution channels. Major trends in the forecast period include rising adoption of biologic and targeted therapies, integration of teleophthalmology and remote monitoring, ai-assisted diagnostic tools for uveitis, growth of personalized eye care solutions, expansion of specialized ophthalmology centers.

Global Paraganglioma Market Segmentation

1) By Type: Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Carotid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Paragangliomas 2) By Origin: Head And Neck, Abdomen, Pelvis, Other Origins 3) By Treatment Type: Peptide Receptor Radionuclide Therapy, Surgery, Chemotherapy, Radiation Therapy, Other Treatment Types 4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes, Other End-Users Subsegments: 1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas, Extra-Adrenal Sympathetic Paragangliomas 2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas, Thoracic Parasympathetic Paragangliomas 3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas, Bilateral Carotid Paragangliomas 4) By Cervical Paragangliomas: Vagal Paragangliomas, Hypoglossal Paragangliomas 5) By Jugular Paragangliomas: Type A, Type B, Type C, Type D 6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas, Non-Catecholamine-Secreting Paragangliomas 7) By Temporal Paragangliomas: Tympanic Paragangliomas, Mastoid Paragangliomas

What Are The Drivers Of The Paraganglioma Market?

The increasing investments in oncology research and medicine are expected to propel the growth of the paraganglioma market going forward. Investments in oncology research and medicine refer to financial allocations made by governments, pharmaceutical companies, research institutions, and private investors to advance the understanding, prevention, diagnosis, and treatment of cancer. The increasing investments in oncology research and medicine are due to the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. Investments in oncology research and medicine support paraganglioma by driving advancements in early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving pediatric cancer care infrastructure, and fostering innovative research to better understand the disease’s biology and progression. For instance, in May 2024, according to IQVIA, an India-based information technology company providing advanced analytics, global spending on cancer medicine rose to $223 billion in 2023, marking a $25 billion increase from 2022, and is expected to reach $409 billion by 2028. Therefore, the increasing investments in oncology research and medicine drive the paraganglioma industry. Growing attention to personalized medicine approaches is expected to propel the growth of the paraganglioma market going forward. Personalized medicine involves tailoring treatment and surveillance on the basis of individual genetic, molecular, or clinical features. Attention to personalized medicine approaches is rising because they enable treatments to be tailored to an individual’s genetic profile, improving efficacy and reducing adverse effects. Paraganglioma particularly benefits because many cases harbor germline pathogenic variants in genes such as SDHB, SDHD, RET, and VHL. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Among these approvals, seven were cancer drugs, while three targeted other diseases and conditions. Therefore, growing attention to personalized medicine approaches is expected to drive the growth of the paraganglioma industry.

Key Players In The Global Paraganglioma Market

Major companies operating in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc. , Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome , National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute

Global Paraganglioma Market Trends and Insights

Major companies operating in the paraganglioma market are focusing on developing advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors to offer targeted therapy options for patients with paraganglioma. An oral HIF-2α inhibitor is a targeted therapy that suppresses HIF-2α activity, a key factor in tumor growth under low-oxygen conditions, helping to slow the progression of cancers like paraganglioma. For instance, in January 2025, Merck, a US-based biopharmaceutical company, announced a priority review for its supplemental new drug application for Welireg (belzutifan), which is granted by the U.S. Food and Drug Administration (FDA), a US-based government agency. It is designed for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The sNDA is based on objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.

Regional Outlook

North America was the largest region in the paraganglioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Paraganglioma Market?

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Paraganglioma Market Report 2026?

The paraganglioma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the paraganglioma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.